These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 33285053)

  • 21. Variants in CDA and ABCB1 are predictors of capecitabine-related adverse reactions in colorectal cancer.
    García-González X; Cortejoso L; García MI; García-Alfonso P; Robles L; Grávalos C; González-Haba E; Marta P; Sanjurjo M; López-Fernández LA
    Oncotarget; 2015 Mar; 6(8):6422-30. PubMed ID: 25691056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thymidylate synthase gene variants as predictors of clinical response and toxicity to fluoropyrimidine-based chemotherapy for colorectal cancer.
    Castro-Rojas CA; Esparza-Mota AR; Hernandez-Cabrera F; Romero-Diaz VJ; Gonzalez-Guerrero JF; Maldonado-Garza H; Garcia-Gonzalez IS; Buenaventura-Cisneros S; Sanchez-Lopez JY; Ortiz-Lopez R; Camacho-Morales A; Barboza-Quintana O; Rojas-Martinez A
    Drug Metab Pers Ther; 2017 Dec; 32(4):209-218. PubMed ID: 29257755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.
    Meulendijks D; Jacobs BA; Aliev A; Pluim D; van Werkhoven E; Deenen MJ; Beijnen JH; Cats A; Schellens JH
    Int J Cancer; 2016 Jan; 138(1):245-53. PubMed ID: 26189437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses.
    Wheeler HE; González-Neira A; Pita G; de la Torre-Montero JC; Alonso R; Lopez-Fernandez LA; Alba E; Martín M; Dolan ME
    Pharmacogenet Genomics; 2014 May; 24(5):231-7. PubMed ID: 24595012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of fluorouracil -based chemotherapy toxicity.
    Matsusaka S; Lenz HJ
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):811-21. PubMed ID: 25800061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele.
    Gusella M; Bolzonella C; Crepaldi G; Ferrazzi E; Padrini R
    Pharmacogenomics J; 2006; 6(6):421-4. PubMed ID: 16868573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
    de With M; van Doorn L; Maasland DC; Mulder TAM; Oomen-de Hoop E; Mostert B; Homs MYV; El Bouazzaoui S; Mathijssen RHJ; van Schaik RHN; Bins S
    Biomed Pharmacother; 2023 Mar; 159():114232. PubMed ID: 36630849
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity.
    Loganayagam A; Arenas Hernandez M; Corrigan A; Fairbanks L; Lewis CM; Harper P; Maisey N; Ross P; Sanderson JD; Marinaki AM
    Br J Cancer; 2013 Jun; 108(12):2505-15. PubMed ID: 23736036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
    O'Donnell PH; Trubetskoy V; Nurhussein-Patterson A; Hall JP; Nath A; Huo D; Fleming GF; Ingle JN; Abramson VG; Morrow PK; Storniolo AM; Forero A; Van Poznak C; Liu MC; Chang JC; Merkel DE; Peppercorn JM; Rugo HS; Dees EC; Hahn OM; Hoffman PC; Rosner GL; Huang RS; Ratain MJ; Cox N; Olopade OI; Wolff AC; Dolan ME; Nanda R;
    Breast Cancer Res Treat; 2020 Jun; 181(3):623-633. PubMed ID: 32378051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.
    Schmulenson E; Krolop L; Simons S; Ringsdorf S; Ko YD; Jaehde U
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):435-444. PubMed ID: 32852627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
    Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
    Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Khalij Y; Belaid I; Chouchane S; Amor D; Omezzine A; Ben Rejeb N; Ben Ahmed S; Bouslama A
    J Chemother; 2023 Sep; 35(5):425-434. PubMed ID: 36137946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evidence of prevention strategies for capecitabine-induced hand-foot syndrome.
    Huang XZ; Chen Y; Chen WJ; Zhang X; Wu CC; Wang ZN; Wu J
    Int J Cancer; 2018 Jun; 142(12):2567-2577. PubMed ID: 29355976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Zhang RX; Wu XJ; Wan DS; Lu ZH; Kong LH; Pan ZZ; Chen G
    Ann Oncol; 2012 May; 23(5):1348-1353. PubMed ID: 21940785
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
    Weekes CD; Nallapareddy S; Rudek MA; Norris-Kirby A; Laheru D; Jimeno A; Donehower RC; Murphy KM; Hidalgo M; Baker SD; Messersmith WA
    Invest New Drugs; 2011 Oct; 29(5):1057-65. PubMed ID: 20306339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
    Baroudi O; Baroudi T; Omrane I; Moussa A; Mezlini A; Ayari H; Guermazi S; Bahloul A; Bouzaienne H; Uhrhammer N; Bignon YJ; El-Gaaied AB; Bougatef K
    Med Oncol; 2014 Feb; 31(2):825. PubMed ID: 24415354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Watts K; Wills C; Madi A; Palles C; Maughan TS; Kaplan R; Al-Tassan NA; Kerr R; Kerr DJ; Houlston RS; Escott-Price V; Cheadle JP
    Int J Cancer; 2022 Sep; 151(6):957-966. PubMed ID: 35467766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
    Meulendijks D; Henricks LM; Jacobs BAW; Aliev A; Deenen MJ; de Vries N; Rosing H; van Werkhoven E; de Boer A; Beijnen JH; Mandigers CMPW; Soesan M; Cats A; Schellens JHM
    Br J Cancer; 2017 May; 116(11):1415-1424. PubMed ID: 28427087
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thymidylate synthase polymorphisms and hematological cancer risk: a meta-analysis.
    Weng Y; Zhang J; Tang X; Xie X; Chen G
    Leuk Lymphoma; 2012 Jul; 53(7):1345-51. PubMed ID: 22166040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thymidylate synthase pharmacogenetics.
    Marsh S
    Invest New Drugs; 2005 Dec; 23(6):533-7. PubMed ID: 16267625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.